Table 2.
Serum transaminases | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Age at onset of treatment (year) | Duration of treatment (year) | Pos. population | Total population | |||||||
Pos. pop. | Total pop. | Pos. pop. | Total pop. | ALAT (U/l) | ASAT (U/l) | γGT (μkat/l) | ALAT (U/l) | ASAT (U/l) | (GT (μkat/l) | |
Kidney transplant | *5 ± 4 | 8 ± 5 | 4 ± 3 | 4 ± 3 | 720 | 800 | 1·6 | 230 | 400 | 0·24 |
70–2480 | 270–1980 | 0·18–10 | 60–2820 | 180–1280 | 0·15–9·6 | |||||
Nephrotic/kidney transplant | 1·3 ± 0·5 | 9 ± 5 | 4·5 ± 2 | 5 ± 3 | ||||||
Nephrotic/ | 2 | 6 ± 3 | 5·5 | 3 ± 2 | ||||||
Liver disease transplant | 3·8 ± 1·3 | 8·6 ± 7 | 1 ± 0 | 3·7 ± 2·5 | ||||||
Total | 4·5 ± 3·5 | 7·6 ± 6 | 4 ± 2·7 | 4 ± 3·2 |
The data shown were obtained from the children described in Table 1. Total = total patient population for which data were available. Age at onset of drug treatments between the patients of positive sera reactivity and the total patient population is statistically significant at
P = 0·1, Student’s unpaired t-test. The values of laboratory tests for serum transaminase are given as the mean and range. NA, Values not available.